Research Article



LncRNA Gm14205 induces astrocytic NLRP3 inflammasome activation via inhibiting oxytocin receptor in postpartum depression

Jialei Zhu and 💿 Jing Tang

Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Huangpu District, Shanghai 200011, China

Correspondence: Jing Tang (1817@fckyy.org.cn)



Postpartum depression (PPD) is a kind of mental disorder characterized by persistent low emotions in puerperium. The most significant physiological change in postpartum is lactation which is regulated by oxytocin receptor (OXTR). However, whether OXTR is related to pathological process of PPD and the potential mechanism still remain unclear. In the present study, we prepared hormone-simulated pregnancy (HSP)-induced PPD mouse model and found that the protein level of OXTR in hippocampus of PPD model mice was down-regulated and Nod-like receptor protein 3 (NLRP3) inflammasome was activated. We identified five long non-coding RNAs (lncRNAs) related to PPD by transcriptome sequencing, including three up-regulated and two down-regulated. The five lncRNAs were associated with the signaling pathway of OXTR according to the bioinformatics analysis. Furthermore, we focused on one of the five lncRNAs, Gm14205, and found that it targeted OXTR which inhibited astrocytic NLRP3 inflammasome activation in hippocampal primary astrocytes. These findings illustrate that OXTR has protective effects in PPD by inhibiting NLRP3 inflammasome activation and provides a new strategy for targeting lncRNA Gm14205 in the pathogenesis of PPD.

Introduction

Postpartum depression (PPD) is a mental disorder characterized by persistent depression in puerperium [1,2]. The main manifestations are depression, insomnia, anxiety, sadness, guilt, irritability and even suicidal tendency [3–5]. It usually attacks in the weeks after delivery and disappears within half a year, but serious cases can last for 1–2 years [6,7]. The pathological mechanism of PPD is still unclear [3,8–10]. PPD not only affects physical and mental health of puerperas, but also deprives infants of the effective care from their mothers, and affects marriage relations [4,11]. Therefore, it is important and urgent to explore the pathological mechanisms of PPD and search for the key target of its development.

The most significant physiological change in postpartum is lactation, and oxytocin is a key molecule mainly secreted in paraventricular nucleus and supraoptic nucleus of hypothalamus that contributes to lactation [12]. It participates in the regulation of cognition, social behavior, addiction [13,14], and also plays an important role in the treatment of psychiatric diseases [15]. Oxytocin exerts physiological functions by binding to oxytocin receptor (OXTR) [16]. OXTRs distribute mainly in hippocampus, hypothalamus, nucleus accumbens and also in uterine smooth muscle cells, vascular endothelial cells, adipocytes [17]. The number of OXTRs in different brain regions is closely related to the social behavior [18,19]. It has been reported that hypermethylation [20,21] and low expression [22] of OXTR may play important roles in the etiology of PPD susceptible phenotypes, suggesting that the post-transcriptional mechanisms may regulate the occurrence of PPD. Therefore, the study of the regulation of OXTR by non-coding RNA may help us understand the mechanism of PPD more deeply.

Received: 12 March 2020 Revised: 04 July 2020 Accepted: 14 July 2020

Accepted Manuscript online: 24 July 2020 Version of Record published: 07 August 2020



Long non-coding RNA (lncRNA) is a non-coding RNA whose length exceeds 200 nt. It plays an important role in epigenetics, DNA methylation, gene silencing or activation, transcription and post-transcriptional regulation [23–25]. Studies have shown that lncRNA may be involved in the pathophysiological process of depression [26]. However, the regulation of lncRNA on PPD, such a special type of depression, has not been reported yet. The scientific significance and applicability of lncRNA in clinical diagnosis and treatment of PPD need to be revealed.

In the present study, we prepared hormone-simulated pregnancy (HSP)-induced mouse model of PPD so as to investigate whether lncRNAs regulate PPD by targeting OXTR. We showed that the protein level of OXTR in hippocampus of PPD model mice was down-regulated and Nod-like receptor protein 3 (NLRP3) inflammasome was activated. We identified five lncRNAs related to PPD by transcriptome sequencing, including three up-regulated and two down-regulated. The five lncRNAs are associated with the signaling pathway of OXTR according to the bioinformatics analysis. Furthermore, we focused on one of the five lncRNAs, Gm14205, and found that it targeted OXTR which inhibited astrocytic NLRP3 inflammasome activation *in vitro*. These findings illustrate that OXTR has protective effects in PPD and provides a new strategy for targeting the lncRNA in the pathogenesis of this disease.

Materials and methods

Animals

C57BL/6J mice (female, 3-month-old) were purchased from SipprBK Laboratory Animals Ltd (Shanghai, China). Mice were bred and maintained in the Animal Resource Centre of the Faculty of Medicine, Fudan University. Mice had free access to food and water in a room with an ambient temperature of $22 \pm 2^{\circ}$ C and a 12:12-h light/dark cycle. All animal procedures were performed in strict accordance with the guidelines of the Institutional Animal Care and Use Committee of Fudan University. The ethics approval has been obtained from Experimental Animal Department of Fudan University.

Reagents

Estradiol benzoate and progesterone were purchased from Aladdin (Shanghai, China). For animal experiments, estradiol benzoate and progesterone were dissolved in sesame oil. Anti-OXTR Ab (#ab217212, 1:300) was purchased from Abcam (Cambridge, U.K.). Anti- β -actin Ab (#BM0627, 1:4000) was purchased from Boster (Pleasanton, CA, U.S.A.). Anti-NLRP3 Ab (#AG-20B-0014-C100, 1:1000) was purchased from AdipoGen (San Diego, CA, U.S.A.). Anti-caspase-1 Ab (#06-503-I, 1:500) and anti-glial fibrillary acidic protein (GFAP) Ab (#MAB360, 1:500) were purchased from Millipore (Billerica, MA, U.S.A.). Anti-IL-1 β Ab (#13767, 1:500) was purchased from Sigma (St. Louis, MO, U.S.A.). Anti-ASC Ab (#SC-22514-R, 1:500) was purchased from Santa Cruz (Dallas, Texas, U.S.A.). Pentobarbital sodium was purchased from Huayehuanyu (Beijing, China).

Mouse model of PPD

Three-month-old female C57BL6J mice were made PPD model induced by HSP [27]. They were ovariectomized bilaterally using aseptic techniques under 1% pentobarbital sodium anesthesia (60 mg/kg, i.p.) and left for 7 days. The ovariectomized mice were injected hypodermically (i.h.) with estradiol benzoate (20 μ g/kg) and progesterone (32 mg/kg) dissolved in sesame oil once a day for 16 consecutive days. Then progesterone was withdrawn and a high dose of estradiol benzoate (400 μ g/kg) was administrated for further 7 days. Control mice were sham-operated and received sesame oil only. Three days after the last injection, behavioral evaluations were carried out. Mice were intraperitoneally injected 1% pentobarbital sodium (60 mg/kg) and then killed by quick cervical vertebra dislocation.

Behavioral evaluations

Sucrose preference test

Sucrose preference was measured prior to ovariectomy and after the hormone injection, on day 0 and 33. Sucrose preference test (SPT) was performed as described previously [28]. After depriving of water for 12 h, mice were given the choice to drink from two bottles containing 1% sucrose solution or tap water, respectively, for 10 h. The positions of the bottles were switched after 5 h to prevent side preference in drinking behavior. The consumption of tap water and sucrose solution was estimated simultaneously in control and PPD groups by weighing the bottles. The preference for sucrose was calculated as a percentage of the consumed sucrose solution relative to the total amount of liquid intake.

Tail suspension test

Tail suspension test (TST) was performed as described previously [28]. Mice tails were wrapped with tape and fixed upside down on the hook. The immobility time of each mouse was recorded for a 6-min period. Mice were considered



immobile only when they hung passively and completely motionless. The time of immobility during the last 4 min was measured with TailSuspScan (Clever Sys).

Forced swim test

Forced swim test (FST) was performed as described previously [28]. Mice were individually forced to swim in an open cylindrical container (25 cm in height and 10 cm in diameter) filled with water at room temperature (approximately $22 \pm 1^{\circ}$ C) to the depth of 14 cm for 6 min. Immobility was defined when the mouse floated in an upright position and made only small movements to keep its head above water for the requirement of respiration. The duration of immobility was recorded during the last 4 min by TailSuspScan (Clever Sys).

Nissl staining

The brain slides were soaked in CV solution containing 0.1 g Cresyl Violet, 99 ml H_2O and 1% acetic acid (1 ml) for 30 min at room temperature, then slides were dehydrated with alcohol and xylene. The slices were observed under stereomicroscope (Olympus).

ELISA

Serum was assayed for oxytocin with ELISA kits from R&D Systems according to the manufacturer's instructions. We set eight tubes of standard products with concentrations of 1000, 500, 250, 125, 62.5, 31.25, 15.625, 0 pg/ml as the abscissa, and the OD value as the ordinate. Then we drew a standard curve. We diluted the samples at a ratio of 1:2 and detected their OD values. According to the standard curve line, we found the corresponding oxytocin contents on the graph, and then multiply the dilution factor of 2.

Real time quantitative-and reverse transcription-PCR

Total RNA was extracted from brain tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.). Reverse transcription (RT) of total RNA was carried out using TaKaRa Master Mix (TaKaRa, Japan). The primers were purchased and validated from Generay (Shanghai, China). Real-time PCR was carried out using SYBR Green Master Mix (Applied Biosystems) in a StepOnePlus instrument (Applied Biosystems). The primers used for qPCR were as follows:

```
OXTR (F): CTCCCACCTATTTCTACTACC
OXTR (R): TCATTTCCCACTCCTTGTC
ENSMUSG0000090031 (F): CTGATGTTTGCCATAAAGAG
ENSMUSG00000090031 (R): AGTTAGGGAAGACAATGAAG
ENSMUSG00000087563 (F): GCCGTGATCTTGGGTTTG
ENSMUSG00000104674 (F): CCCTTCAACTCCTTGGGTCC
ENSMUSG00000104674 (R): CCCAGGCTGGTGATTTCAGT
ENSMUSG00000109754 (F): TAGGCAAGAACTTCACGGTAG
ENSMUSG00000109754 (R): CTCTTTGTATGCCTGCGAATC
ENSMUSG00000045238 (F): TCGCATCAGTGCTGTGAAGT
ENSMUSG00000045238 (R): CGTCTTTCACGTGGAACCCT
GAPDH (F): CTGCCCAGAACATCATCC
GAPDH (R): CTCAGATGCCTGCTAC
```

Western blotting analysis

Western blotting analysis was performed as described previously [29]. Brain tissues or cells were lysed in the buffer (Bio-Rad). Proteins were separated by SDS/PAGE using polyacrylamide TGX gels (Bio-Rad, Hercules, CA, U.S.A.) and then transferred to polyvinylidene difluoride (PVDF) membranes. After blocking, membranes were incubated with various specific primary antibodies as described above in TBST at 4°C overnight. Membranes were washed and incubated in corresponding secondary antibodies (1:1000, KPL) for 1 h at room temperature. Proteins were visualized and detected by enhanced chemiluminescence reagents (Pierce, Thermo Fisher Scientific) and analyzed with ImageQuant[™] LAS 4000 imaging system (GE Healthcare, Pittsburgh, PA, U.S.A.).

Immunocytochemical staining

Brain slides or astrocytes were rinsed with 0.1 M PBS and fixed with 4% paraformaldehyde, followed by block with PBS containing 5% bovine serum albumin, then incubated with the primary antibody (anti-GFAP Ab or anti-NLRP3



Ab) at 4°C overnight. After washing, brain slides or cells were exposed to fluorescent secondary antibody for 1 h at room temperature. After washing and treatment with DAPI (Life), cells were observed under stereomicroscope (Olympus, Tokyo, Japan).

Transcriptome sequencing and bioinformatics analysis

The hippocampus was obtained for transcriptome sequencing using Illumina Truseq[™] RNA Sample Prep Kit and bioinformatics analysis by Ucdom (Shanghai, China).

Hippocampal primary astrocyte cultures and cell transfection

Mouse primary astrocyte cultures were conducted as described previously [29]. Plasmid of Gm14205, siRNA targeting OXTR or negative control (NC) siRNA (Jima, Shanghai, China) were transfected in primary astrocytes using Lipofectamine 3000 reagent (Invitrogen, Life Technologies) according to the manufacturer's instructions. After 72 h, cells were collected for experiments.

Statistical analysis

Data were presented as mean \pm SEM. The significance of difference was determined by Student's *t* test and two-factor analysis of variance. Difference was considered significant at *P* < 0.05.

Results HSP-induced PPD model mice exhibit depressive-like behaviors

The ovariectomized mice were subcutaneously injected with estradiol benzoate and progesterone to prepare PPD mouse model. SPT, FST, and TST were used for the evaluation of depressive-like behaviors, and the whole procedure is shown in Figure 1A. At the beginning of SPT, there was no significant difference in sucrose preference between two groups, while the sucrose preference rate of HSP group decreased by $11.10 \pm 3.441\%$ (Interaction F(1, 32) = 5.423, P=0.0263; Model F(1, 32) = 6.149, P=0.0186; HSP F(1, 32) = 13.28, P=0.0009) after modeling (Figure 1B). As shown in FST, the immobility time of HSP group increased by 65.47 ± 9.647 s (two-tailed, t = 6.786, df = 10, P<0.001) compared with control group after modeling (Figure 1C). Similarly, the immobility time of HSP group increased by 70.06 ± 5.090 s (two-tailed, t = 13.76, df = 10, P<0.001) in TST (Figure 1D). The Nissl staining results showed that the granule cells in the DG region and the vertebral cells in CA1 and CA3 regions of HSP group were loosely arranged (Figure 1E). The cell bodies became smaller, the nucleoli contracted, and the cells number decreased (Figure 1F) (DG: two-tailed, t = 4.802, df = 10, P<0.001; CA1: two-tailed, t = 3.968, df = 10, P=0.0027; CA3: two-tailed, t = 7.482 df = 10, P<0.001). The results above suggested that the establishment of PPD model was successful.

The protein level of OXTR in hippocampus of PPD model mice was down-regulated

To explore the pathological mechanism of PPD, we detected the levels of oxytocin in serum of mice. As shown in Figure 2A, oxytocin was down-regulated in HSP group (two-tailed, t = 5.789, df = 30, P < 0.001), suggesting the correlation between oxytocin and PPD. Then we respectively collected cortex, hippocampus, hypothalamus, cerebellum of mice and detected the expression of OXTR by real time-PCR and Western blot. As shown in Figure 2B, the mRNA level of OXTR was unchanged after modeling (cortex P=0.601; hippocampus P=0.7616; hypothalamus P=0.5058; cerebellum P=0.3416). The protein levels of OXTR in the four brain regions were all down-regulated (cortex P=0.0237; hippocampus P=0.012; hypothalamus P=0.0333; cerebellum P=0.0456) (Figure 2C,D). Notably, OXTR expressed in hippocampus was higher than that expressed in other brain regions, suggesting that hippocampus may be most closely related to PPD.

NLRP3 inflammasome was activated in hippocampus of PPD model mice

Considering that the mRNA level of OXTR in PPD model mice is not significantly reduced while the hippocampal neurons are remarkably lost, we speculate that non-neuronal cells which express OXTR are involved in the pathological process of PPD. Neuroinflammation is a common feature of many neurodegenerative diseases like depression [30]. It is mainly caused by activated glial cells and manifests as the secretion of inflammatory cytokines. Astrocytes are the most abundant glial cells in the brain, and they play a pivotal role in regulating inflammatory response in a variety of neurodegenerative diseases [31]. In order to investigate whether they are related to PPD, we detect the GFAP, a marker of astrocytes, by immunofluorescence. As shown in Figure 3A, the number of GFAP⁺ cells in the






Figure 1. Behavioral evaluations of PPD model mice

(A) The schedule of HSP-induced PPD mouse model and behavioral tests. Female C57BL6J mice were ovariectomized bilaterally and left for 7 days. The ovariectomized mice were i.h. with estradiol benzoate (20 μ g/kg) and progesterone (32 mg/kg) once a day for 16 consecutive days. Then progesterone was withdrawn and a high dose of estradiol benzoate (400 μ g/kg) was administrated for further 7 days. (B) Sucrose preference rate of SPT. (C) Immobility time of FST. (D) Immobility time of TST. (E) Nissl staining of DG, CA1, CA3 regions. (F) Counting of neuronal cells in DG, CA1, CA3 regions. Scale bar represents 100 μ m. **P<0.01, ***P<0.001 vs Corresponding saline group, #P<0.01 vs HSP 0 day group. Values are means \pm SEM. Data are representative of at least five independent experiments. Abbreviation: OVX, ovariectomy.

hippocampal DG, CA1, and CA3 regions of model mice did not change significantly compared with the saline group. And we found that the astrocytic protrusions in the hippocampal region of PPD model mice were long and thin, showing an active state (Figure 3B). Furthermore, we observed that NLRP3 inflammasome (two-tailed, t = 3.667, df = 4, P=0.0215) was activated and the proinflammatory cytokine interleukin-1 β (IL-1 β) (two-tailed, t = 5.251, df = 4, P=0.0063) was secreted in hippocampus of PPD model mice (Figure 3C,D).






Figure 2. Expressions of oxytocin and OXTR in PPD model mice

(A) Serum of mice was collected and oxytocin was detected by ELISA. (B) mRNA levels of OXTR in hippocampus, cortex, hypothalamus, cerebellum was analyzed by qRT-PCR. (C) OXTR expressed in hippocampus, cortex, hypothalamus, cerebellum of mice was analyzed by immunoblotting. (D) Densitometric analysis of OXTR. *P<0.05, ***P<0.001 vs Corresponding saline group. Values are means \pm SEM. Data are representative of at least three independent experiments.

Table 1 Differentially expressed IncRNAs between control and PPD groups

ld	Туре	Name	log2FC (GD/GC)	P-value	FDR	Regulation
ENSMUSG0000090031	IncRNA	4732440D04Rik	2.641215914	3.16E-12	9.03E-09	up
ENSMUSG00000109754	IncRNA	Gm39214	-2.672129766	5.69E-10	1.22E-06	down
ENSMUSG0000087563	IncRNA	Gm14205	7.723717533	2.09E-08	3.59E-05	up
ENSMUSG0000045238	IncRNA	A730035I17Rik	-1.926173533	2.94E-05	0.021068064	down
ENSMUSG00000104674	IncRNA	Gm42756	1.531618517	5.83E-05	0.032296743	up

To avoid false positive errors, multiple test correction method was used to correct the significant P-value obtained from the original hypothesis test, and finally FDR was used as key index for screening differentially expressed genes. FDR < 0.05.


Non-coding RNA expression profiling in hippocampus of mice

Considering the protein level of OXTR in hippocampus of PPD model mice was down-regulated while the mRNA level of it in hippocampus was unchanged, it suggested that post-transcriptional mechanism played a role in the pathological process. Therefore, differentially expressed non-coding RNAs in hippocampus were identified using transcriptome sequencing. As shown in Supplementary Table, we found 27 differentially expressed genes (|log2FC|>1 and FDR < 0.05. FC, fold change; FDR, false discovery rate), including five differentially expressed lncRNAs. Among the five differentially expressed lncRNAs (Table 1), three were up-regulated (ENSMUSG00000090031, ENSMUSG0000045238). The overall distribution of the differential genes can be inferred by visualizing the scatter plot (Figure 4A) and volcano plot (Figure 4B). To validate the transcriptome sequencing results, we used qRT-PCR to detect the differentially expressed lncRNAs. As shown in Figure 4C–G (P<0.001), the qRT-PCR results were concordant with the transcriptome sequencing data.

Gene Ontology and KEGG analysis of differentially expressed genes

After the transcriptome sequencing, we performed the bioinformatics analysis. Using Gene Ontology (GO) database, genes can be classified according to the biological processes (BP) in which they participate, the cellular components (CCs) that make up the cells, and the molecular functions (MF) that are achieved. The top 20 enriched terms of differentially expressed genes in the BP, CC, and MF terms are presented in Figure 5A, including extracellular region,





(**A**,**B**) GFAP⁺ cells in hippocampus were detected by immunofluorescence. GFAP⁺ cells were marked by green fluorescence. (**C**) NLRP3, pro-caspase-1, caspase-1, pro-IL-1 β and IL-1 β expressed in hippocampus were analyzed by immunoblotting. (**D**) Densitometric analysis of NLRP3, caspase-1, pro-IL-1 β and IL-1 β . Scale bar represents 50 μ m. **P*<0.05, ***P*<0.01 vs saline group. Values are means \pm SEM. Data are representative of at least three independent experiments.

cellular response to organic substance, MF regulator, cell adhesion, biological adhesion, etc. In terms of the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of our study, a total of 108 signaling pathways were enriched, and the top 8 are listed in Figure 5B. Among those pathways, 'neuroactive ligand-receptor interaction' was enriched the most, followed by calcium signaling pathway, chemokine signaling pathway, regulation of action cytoskeleton,




Figure 4. Validation of differentially expressed IncRNAs by qRT-PCR after RNA-seq (A) Scatter plot and (B) volcano plot of the differentially expressed genes. The transverse and vertical coordinates are logarithmized. Each point represents a specific gene or transcript. The red dots indicate genes that are significantly up-regulated, the blue dots indicate genes that are significantly down-regulated, and the black dots are non-significantly differentially expressed genes. (C–G) Differentially expressed IncRNAs were detected by qRT-PCR. ***P<0.001 vs Corresponding saline group. Values are means \pm SEM. Data are representative of at least three independent experiments.

etc. Notably, OXTR signaling is closely associated with the mostly enriched pathway 'neuroactive ligand-receptor interaction'. Therefore, we speculated that lncRNA regulates PPD by targeting OXTR.

LncRNA Gm14205 negatively regulated OXTR and activated NLRP3 inflammasome

Among the five differentially expressed lncRNAs, the expression of ENSMUSGC00000087563 (Gm14205) varied the most (RNA-seq: |log2FC| = 7.7237, FDR = 3.59E-05; qRT-PCR: 26.1-fold, P=0.0007). Thus, we cultured mouse hippocampal primary astrocytes and explored the effect of lncRNA Gm14205 on regulating OXTR. As shown in Figure 6A–C, after transfecting plasmid which carries lncRNA Gm14205 in liposome (qRT-PCR: 20.97-fold, P=0.0181), the protein level of OXTR was down-regulated (two-tailed, t = 3.293, df = 4, P=0.0301). It suggested that lncRNA Gm14205 targets OXTR. Cell morphology was observed under the bright field, and the protrusions of astrocytes transfected with lncRNA Gm14205 plasmid were long and thin (Figure 6D). The immunofluorescence (Figure 6E)




Figure 5. GO and KEGG enrichment analyses

(A) GO enrichment results in scatter diagram, the top 30 GO categories are listed. All the genes/transcripts were selected as background lists, and the differentially expressed genes/transcripts were selected as candidate lists from background lists. Fisher's exact test was used. In order to control the calculated false positive rate, four multiple tests (Bonferroni, Holm, Sidak, and FDR) were used to correct the *P*-value. Generally, when the corrected *P*-value (*P*_fdr) is less than 0.05, it is considered that the GO function is significantly enriched. (B) Top eight enriched signaling pathways from KEGG analysis. Fisher exact test is used for calculation. In order to control the false positive rate, BH (FDR) method was used to carry out multiple tests. Corrected *P*-value was defined as a KEGG pathway with a threshold of 0.05.




Figure 6. The regulation of IncRNA Gm14205 to OXTR and NLRP3

(A) Transfected IncRNA Gm14205 were measured by qRT-PCR. (B) OXTR expressed in primary astrocytes was analyzed by immunoblotting. After transfecting IncRNA Gm14205 in primary astrocytes, the protein level of OXTR was detected. (C) Densitometric analysis of OXTR. (D) Cell morphology was observed under the bright field. (E) NLRP3 and ASC were detected by immunofluorescence in primary astrocytes transfected with Gm14205 plasmid or not. NLRP3 was marked by green fluorescence and ASC was marked by red fluorescence. (F) NLRP3, pro-caspase-1, caspase-1, pro-IL-1 β and IL-1 β expressed in astrocytes were analyzed by immunoblotting. (G) Densitometric analysis of NLRP3, caspase-1, pro-IL-1 β and IL-1 β . (H) NLRP3 in primary astrocytes was detected by immunofluorescence. Scale bar represents 20 μ m. **P*<0.05, ***P*<0.01 vs Mock group. Values are means ± SEM. Data are representative of at least three independent experiments.



showed that NLRP3 was up-regulated and ASC speck was formated, suggesting that NLRP3 inflammasome was activated. We collected and extracted the proteins in the cell cytoplasm and supernatant respectively, and detected the levels of NLRP3, IL-1 β /pro-IL-1 β , caspase-1/pro-caspase-1. The results (Figure 6F,G) showed that the secretion of IL-1 β (two-tailed, t = 4.571, df = 4, P=0.0103) and caspase-1 (two-tailed, t = 4.232, df = 4, P=0.0133) are increased in the cell supernatant, and the level of NLRP3 (two-tailed, t = 4.441, df = 4, P=0.0113), and pro-IL-1 β (Two-tailed, t = 4.092, df = 4, P=0.0150) in the cytoplasm was up-regulated, which also suggesting that NLRP3 inflammasome was activated. Furthermore, we delineated the effect of OXTR on NLRP3 inflammasome activation by interfering OXTR. Immunofluorescence result showed that knockdown of OXTR (Figure 6H) activated NLRP3 inflammasome. These results indicated that lncRNA Gm14205-OXTR-NLRP3 axis may be a possible pathological mechanism in PPD.

Discussion

Modern women are under great pressure of work and life, and the incidence of PPD is also on the rise [11]. PPD not only seriously damages women's physical and mental health, but also brings harmful impact on the healthy growth of infants, family harmony, and social stability [32]. Its pathological mechanisms have not been fully elucidated yet, and researches usually involve monoamine transmitter deficiency, neuroendocrine disorder, neurotrophic factor endocrine reduction, oxidative stress, neuroinflammation hypothesis, etc [3,33]. However, most of the studies focus on depression itself, ignoring the important attribute of 'postpartum'. Thus, it reminds us that we should search for some targets that relate to the puerperium. Recently, Zulresso [34,35] (brexanolone injection, an allosteric regulator that can simultaneously act on synaptic and extrasynaptic GABA_A receptors), developed by Sage Therapeutics Biopharmaceutical Company, has got the approval of the Food and Drug Administration (FDA) for the first drug specializing in treatment of PPD. It reflects from the side that the research field on PPD still has a very broad space. Oxytocin and OXTR are closely related to childbirth and lactation, and they also play important roles in the treatment of some psychiatric diseases [36]. Previous study has shown that injection of exogenous oxytocin into the paraventricular nucleus of hypothalamus can improve the depression-like behavior of PPD model rats and play an anti-PPD role [37]. Our study showed that oxytocin was down-regulated in HSP group. The result is consistent with previous report. We also found the protein level of OXTR in hippocampus of PPD model mice was down-regulated. These findings imply that OXTR may be a promising target for the therapy of PPD.

Astrocytes have a basic physiological function in forming borders to restrict access of leukocyte into brain parenchyma [31]. They also provide energy sources for neurons, modulate synaptic activity, and regulate extracellular glutamate levels [38]. Astrocytes have been reported to be associated with many kinds of neurodegenerative disease like depression [39,40]. Previous studies showed that neuroinflammation reactions occur in multiple brain regions in animal models with depression [41,42]. Our study also revealed that astrocytes and NLRP3 inflammasome in hippocampus of PPD model mice were activated and caused the subsequent the secretion of proinflammatory cytokine IL-1 β . In addition, previous animal models of depression [43,44] showed that the number and density of astrocytes are significantly decreased compared with normal cases. Interestingly, in our present study, astrocytes just activate rather than obviously lose in PPD model mice. Perhaps it revealed the differences of pathology between PPD and ordinary depression. The in-depth mechanism is currently unknown and deserves further explorations.

It has been reported that hypermethylation and low expression of OXTR may play an important role in the etiology of PPD susceptible phenotypes [20-22], suggesting that their post-transcriptional mechanisms may regulate the occurrence of PPD. Our study showed that the protein level of OXTR was decreased while the mRNA level was unchanged, suggesting a potential post-transcriptional mechanism as well. Post-transcriptional regulation refers to the regulation of gene expression after RNA transcription and is one of the characteristics of eukaryotic gene expression [45,46]. Studies have shown that lncRNA may participate in the pathophysiological process of depression and regulate DNA transcription and chromosome remodeling [26,47]. It has been reported that the expression of lncRNA in peripheral blood mononuclear cells of depressive patients is significantly down-regulated. However, the regulatory effect of lncRNA on PPD, such a special type of depression, has not been reported yet. In the present study, we identified five lncRNAs related to PPD by transcriptome sequencing, including three up-regulated (ENSMUSG0000090031, ENSMUSG00000087563, ENSMUSG00000104674) and two down-regulated (ENSMUSG00000109754, ENSMUSG00000045238). The five lncRNAs are associated with the signaling pathway of OXTR according to the bioinformatics analysis. Furthermore, we found that overexpression of lncRNA Gm14205, a lncRNA with the biggest variation among the five differentially expressed lncRNAs, inhibited the protein level of OXTR in hippocampal primary astrocytes, and knockdown of OXTR-activated NLRP3 inflammasome. The results above suggest that lncRNA Gm14205 may be a crucial biological target in PPD.






Figure 7. Schematic diagram of the anti-inflammasome effect of IncRNA Gm14205 targeting OXTR A proposed model for how IncRNA Gm14205 regulates OXTR and modulates NLRP3 inflammasome activation in hippocampal astrocytes in PPD.

In summary, our study reveals a novel function of lncRNA Gm14205–OXTR–NLRP3 axis in the pathology of PPD as shown in Figure 7. However, there are further experiments worthy doing to enrich our studies: (1) our study shows that astrocytic OXTR in hippocampus may play an important role in PPD. However, we do not know whether OXTR in other kinds of glial cells like microglia also has the function. Microglia are the most sensitive cells to inflamma-some responses in the CNS, and it is very meaningful to check for microglial inflammasome activation. Further studies using astrocytic and microglial OXTR conditional knockout mice (OXTRloxp/loxp; GFAP-cre; OXTR loxp/loxp; Iba1-cre) will provide more conclusive evidence. (2) We speculate that lncRNA Gm14205 inhibited OXTR possibly through a post-transcriptional regulation, but the precise mechanism remains unknown. We did not investigate that the reduction in OXTR may occur at the protein level, instead of the mRNA level. The ubiquitination degradation of OXTR protein may also be involved in the pathological process. Further explorations will be done to confirm and enrich the study. (3) Except lncRNA Gm14205, other four differentially expressed lncRNAs may also play roles in PPD, and further studies deserve to be done to expand our researches. Collectively, these results illustrate that OXTR has protective effects by suppressing NLRP3 inflammasome activation and provide a new strategy for targeting lncRNA Gm14205 in the pathogenesis of PPD. It will help us accumulate academic basis for clinical diagnosis and drug development, promoting the translation from basic research to clinical application.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Key Specialized Construction Projects of Clinical Pharmacy of Shanghai [grant number AB83110002017005].

Author Contribution

Jialei Zhu did the experiments, analyzed the data and wrote the manuscript. Jing Tang guided the whole experiment and revised the article.



Acknowledgements

We thank Ucdom company for transcriptome sequencing and bioinformatics analysis. We thank Daxiao Xu for assistance in making figures.

Abbreviations

Ab, anti-body; ASC, Apoptosis-associated speck-like protein containing a CARD; BP, biological process; CV, cresyl violet; DAPI, 4',6-diamidino-2-phenylindole; FC, fold change; FDR, false discovery rate; FST, forced swim test; GABA, gamma-aminobutyric acid; GFAP, glial fibrillary acidic protein; GO, Gene Ontology; HSP, hormone-simulated pregnancy; i.p., intra-peritonelly; IL-1β, interleukin-1β; IncRNA, long non-coding RNA; MF, molecular function; NLRP3, Nod-like receptor protein 3; OD, optical density; OXTR, oxytocin receptor; PPD, postpartum depression; SPT, sucrose preference test; TBST, Tris Buffered saline Tween; TST, tail suspension test.

References

- 1 Jones, I. (2017) Post-partum depression-a glimpse of light in the darkness? Lancet 390, 434–435, https://doi.org/10.1016/S0140-6736(17)31546-5
- 2 Anderson, C.A. and Connolly, J.P. (2018) Predicting posttraumatic stress and depression symptoms among adolescents in the extended postpartum period. *Heliyon* **4**, e00965, https://doi.org/10.1016/j.heliyon.2018.e00965
- 3 Payne, J.L. and Maguire, J. (2018) Pathophysiological mechanisms implicated in postpartum depression. Front. Neuroendocrinol. 52, 165–180, https://doi.org/10.1016/j.yfrne.2018.12.001
- 4 Grigoriadis, S., Graves, L., Peer, M., Mamisashvili, L., Tomlinson, G., Vigod, S.N. et al. (2018) A systematic review and meta-analysis of the effects of antenatal anxiety on postpartum outcomes. *Arch. Womens Ment. Health*, vol. **22**, pp. 543–556, https://doi.org/10.1007/s00737-018-0930-2
- 5 Lin, Y.H., Chen, C.M., Su, H.M., Mu, S.C., Chang, M.L., Chu, P.Y. et al. (2019) Association between postpartum nutritional status and postpartum depression symptoms. *Nutrients* **11**, 1204, https://doi.org/10.3390/nu11061204
- 6 Chen, J., Cross, W.M., Plummer, V., Lam, L. and Tang, S. (2018) A systematic review of prevalence and risk factors of postpartum depression in Chinese immigrant women. *Women Birth* 32, 487–492, https://doi.org/10.1016/j.wombi.2018.11.019
- 7 Falana, S.D. and Carrington, J.M. (2019) Postpartum depression: are you listening? *Nurs. Clin. North Am.* **54**, 561–567, https://doi.org/10.1016/j.cnur.2019.07.006
- 8 Garcia-Leal, C., De Rezende, M.G., Corsi-Zuelli, F., De Castro, M. and Del-Ben, C.M. (2017) The functioning of the hypothalamic-pituitary-adrenal (HPA) axis in postpartum depressive states: a systematic review. *Expert Rev. Endocrinol. Metab.* **12**, 341–353, https://doi.org/10.1080/17446651.2017.1347500
- 9 Cao, S., Jones, M., Tooth, L. and Mishra, G.D. (2020) History of premenstrual syndrome and development of postpartum depression: a systematic review and meta-analysis. *J. Psychiatr. Res.* **121**, 82–90, https://doi.org/10.1016/j.jpsychires.2019.11.010
- 10 Diop, S., Turmes, L., Juckel, G. and Mavrogiorgou, P. (2019) Postpartum depression and migration. *Nervenarzt*, [published online ahead of print, 2019 Nov 12], https://doi.org/10.1007/s00115-019-00828-5
- 11 Wszolek, K., Zurawska, J., Luczak-Wawrzyniak, J., Kopaszewska-Bachorz, B., Glowinska, A. and Pieta, B. (2018) Postpartum depression a medical or a social problem? *J. Matern. Fetal Neonatal. Med.* **33**, 1–141
- 12 Cilz, N.I., Cymerblit-Sabba, A. and Young, W.S. (2018) Oxytocin and vasopressin in the rodent hippocampus. *Genes Brain Behav.* **18**, e12535, https://doi.org/10.1111/gbb.12535
- 13 Engel, S., Laufer, S., Knaevelsrud, C. and Schumacher, S. (2018) The endogenous oxytocin system in depressive disorders: A systematic review and meta-analysis. *Psychoneuroendocrinology* **101**, 138–149, https://doi.org/10.1016/j.psyneuen.2018.11.011
- 14 Lopatina, O.L., Komleva, Y.K., Gorina, Y.V., Olovyannikova, R.Y., Trufanova, L.V., Hashimoto, T. et al. (2018) Oxytocin and excitation/inhibition balance in social recognition. *Neuropeptides* **72**, 1–11, https://doi.org/10.1016/j.npep.2018.09.003
- 15 Lara-Cinisomo, S., McKenney, K., Di Florio, A. and Meltzer-Brody, S. (2017) Associations between postpartum depression, breastfeeding, and oxytocin levels in Latina mothers. *Breastfeed. Med.* **12**, 436–442, https://doi.org/10.1089/bfm.2016.0213
- 16 Damien, G. (2018) Oxytocin testing and reproductive health: status and clinical applications. Clin. Biochem. 62, 55–61
- 17 Lin, Y.T. and Hsu, K.S. (2018) Oxytocin receptor signaling in the hippocampus: role in regulating neuronal excitability, network oscillatory activity, synaptic plasticity and social memory. *Prog. Neurobiol.* **171**, 1–14, https://doi.org/10.1016/j.pneurobio.2018.10.003
- 18 Kraaijenvanger, E.J., He, Y., Spencer, H., Smith, A.K., Bos, P.A. and Boks, M.P.M. (2018) Epigenetic variability in the human oxytocin receptor (OXTR) gene: A possible pathway from early life experiences to psychopathologies. *Neurosci. Biobehav. Rev.* 96, 127–142, https://doi.org/10.1016/j.neubiorev.2018.11.016
- 19 Mattson, R.E., Cameron, N., Middleton, F.A., Starr, L.R., Davila, J. and Johnson, M.D. (2018) Oxytocin receptor gene (OXTR) links to marital quality via social support behavior and perceived partner responsiveness. *J. Fam. Psychol.*
- 20 Kimmel, M., Clive, M., Gispen, F., Guintivano, J., Brown, T., Cox, O. et al. (2016) Oxytocin receptor DNA methylation in postpartum depression. *Psychoneuroendocrinology* **69**, 150–160, https://doi.org/10.1016/j.psyneuen.2016.04.008
- 21 King, L., Robins, S., Chen, G., Yerko, V., Zhou, Y., Nagy, C. et al. (2017) Perinatal depression and DNA methylation of oxytocin-related genes: a study of mothers and their children. *Horm. Behav.* 96, 84–94, https://doi.org/10.1016/j.yhbeh.2017.09.006
- 22 Saphire-Bernstein, S., Way, B.M., Kim, H.S., Sherman, D.K. and Taylor, S.E. (2011) Oxytocin receptor gene (OXTR) is related to psychological resources. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 15118–15122, https://doi.org/10.1073/pnas.1113137108



- 23 Gagliardi, S., Pandini, C., Garofalo, M., Bordoni, M., Pansarasa, O. and Cereda, C. (2018) Long non coding RNAs and ALS: still much to do. *Noncoding RNA Res.* **3**, 226–231, https://doi.org/10.1016/j.ncrna.2018.11.004
- 24 Akhade, V.S., Pal, D. and Kanduri, C. (2017) Long noncoding RNA: genome organization and mechanism of action. Adv. Exp. Med. Biol. 1008, 47–74, https://doi.org/10.1007/978-981-10-5203-3'2
- 25 Wong, W.K.M., Sorensen, A.E., Joglekar, M.V., Hardikar, A.A. and Dalgaard, L.T. (2018) Non-coding RNA in pancreas and beta-cell development. Noncoding RNA 4, 41, https://doi.org/10.3390/ncrna4040041
- 26 Cui, X., Sun, X., Niu, W., Kong, L., He, M., Zhong, A. et al. (2016) Long non-coding RNA: potential diagnostic and therapeutic biomarker for major depressive disorder. *Med. Sci. Monit.* 22, 5240–5248, https://doi.org/10.12659/MSM.899372
- 27 Galea, L.A., Wide, J.K. and Barr, A.M. (2001) Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. *Behav. Brain Res.* **122**, 1–9, https://doi.org/10.1016/S0166-4328(01)00170-X
- 28 Du, R.H., Tan, J., Sun, X.Y., Lu, M., Ding, J.H. and Hu, G. (2016) Fluoxetine inhibits NLRP3 inflammasome activation: implication in depression. Int. J. Neuropsychopharmacol. 19, pyw037, https://doi.org/10.1093/ijnp/pyw037
- 29 Zhu, J., Hu, Z., Han, X., Wang, D., Jiang, Q., Ding, J. et al. (2018) Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. *Cell Death Differ.* **25**, 2037–2049, https://doi.org/10.1038/s41418-018-0127-2
- 30 Liu, C.H., Yang, M.H., Zhang, G.Z., Wang, X.X., Li, B., Li, M. et al. (2020) Neural networks and the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation in depression. *J. Neuroinflammation* **17**, 54, https://doi.org/10.1186/s12974-020-01732-5
- 31 Novellino, F., Sacca, V., Donato, A., Zaffino, P., Spadea, M.F., Vismara, M. et al. (2020) Innate immunity: a common denominator between neurodegenerative and neuropsychiatric diseases. *Int. J. Mol. Sci.* **21**, 1115, https://doi.org/10.3390/ijms21031115
- 32 Brummelte, S. and Galea, L.A. (2016) Postpartum depression: etiology, treatment and consequences for maternal care. *Horm. Behav.* 77, 153–166, https://doi.org/10.1016/j.yhbeh.2015.08.008
- 33 Menard, C., Hodes, G.E. and Russo, S.J. (2016) Pathogenesis of depression: Insights from human and rodent studies. *Neuroscience* **321**, 138–162, https://doi.org/10.1016/j.neuroscience.2015.05.053
- 34 Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C.N., Deligiannidis, K.M., Rubinow, D.R. et al. (2018) Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet* **392**, 1058–1070, https://doi.org/10.1016/S0140-6736(18)31551-4
- 35 (2019) Brexanolone (Zulresso) for postpartum depression. Med. Lett. Drugs Ther. 61, 68-70
- 36 Gulliver, D., Werry, E., Reekie, T.A., Katte, T.A., Jorgensen, W. and Kassiou, M. (2018) Targeting the oxytocin system: new pharmacotherapeutic approaches. *Trends Pharmacol. Sci.* 40, 22–37, https://doi.org/10.1016/j.tips.2018.11.001
- 37 Wang, T., Shi, C., Li, X., Zhang, P., Liu, B., Wang, H. et al. (2018) Injection of oxytocin into paraventricular nucleus reverses depressive-like behaviors in the postpartum depression rat model. *Behav. Brain Res.* 336, 236–243, https://doi.org/10.1016/j.bbr.2017.09.012
- 38 Fullana, N., Gasull-Camos, J., Tarres-Gatius, M., Castane, A., Bortolozzi, A. and Artigas, F. (2020) Astrocyte control of glutamatergic activity: downstream effects on serotonergic function and emotional behavior. *Neuropharmacology* **166**, 107914, https://doi.org/10.1016/j.neuropharm.2019.107914
- 39 Eldomiaty, M.A., Makarenko, O., Hassan, Z.A., Almasry, S.M., Petrov, P. and Elnaggar, A.M. (2020) Contribution of glia cells specifically astrocytes in the pathology of depression: immunohistochemical study in different brain areas. *Folia Morphol. (Warsz)*, [published online ahead of print, 2020 Feb 5], https://doi.org/10.5603/FM.a2020.0007
- 40 Tao, X., Yan, M., Wang, L., Zhou, Y., Wang, Z., Xia, T. et al. (2020) Homeostasis imbalance of microglia and astrocytes leads to alteration in the metabolites of the Kynurenine pathway in LPS-induced depressive-like mice. *Int. J. Mol. Sci.* **21**, 1460, https://doi.org/10.3390/ijms21041460
- 41 Cheng, J.H., Xu, X., Li, Y.B., Zhao, X.D., Aosai, F., Shi, S.Y. et al. (2020) Arctigenin ameliorates depression-like behaviors in Toxoplasma gondii-infected intermediate hosts via the TLR4/NF-kappaB and TNFR1/NF-kappaB signaling pathways. *Int. Immunopharmacol.* 82, 106302, https://doi.org/10.1016/j.intimp.2020.106302
- 42 Wang, R., Wang, W., Xu, J., Liu, D., Wu, H., Qin, X. et al. (2020) Jmjd3 is involved in the susceptibility to depression induced by maternal separation via enhancing the neuroinflammation in the prefrontal cortex and hippocampus of male rats. *Exp. Neurol.* **328**, 113254, https://doi.org/10.1016/i.expneurol.2020.113254
- 43 Shu, X., Sun, Y., Sun, X., Zhou, Y., Bian, Y., Shu, Z. et al. (2019) The effect of fluoxetine on astrocyte autophagy flux and injured mitochondria clearance in a mouse model of depression. *Cell Death Dis.* **10**, 577, https://doi.org/10.1038/s41419-019-1813-9
- 44 Gong, Y., Sun, X.L., Wu, F.F., Su, C.J., Ding, J.H. and Hu, G. (2012) Female early adult depression results in detrimental impacts on the behavioral performance and brain development in offspring. *CNS Neurosci. Ther.* **18**, 461–470, https://doi.org/10.1111/j.1755-5949.2012.00324.x
- 45 Ayers, D. and Scerri, C. (2018) Non-coding RNA influences in dementia. Noncoding RNA Res. 3, 188–194, https://doi.org/10.1016/j.ncrna.2018.09.002
- 46 Klinge, C.M. (2018) Non-coding RNAs in breast cancer: intracellular and intercellular communication. *Noncoding RNA* **4**, 40, https://doi.org/10.3390/ncrna4040040
- 47 Wang, Q., Roy, B. and Dwivedi, Y. (2019) Co-expression network modeling identifies key long non-coding RNA and mRNA modules in altering molecular phenotype to develop stress-induced depression in rats. *Transl. Psychiatry* **9**, 125, https://doi.org/10.1038/s41398-019-0448-z

id type name log2FC(GD/GC) pval fdr regulate ENSMUSG0000005404 mRNA Skidal -4.059131148 4.22E-47 7.25E-43 down ENSMUSG00000035004 mRNA Hth1 2.816998418 6.35E-16 5.45E-12 up ENSMUSG00000038178 mRNA Slc43a2 1.403245835 1.44E-15 8.24E-12 up ENSMUSG0000003640 mRNA Ngp -3.032195491 7.20E-13 3.09E-09 down ENSMUSG000000103677 mRNA Pedhga4 -2.444296501 1.31E-12 4.50E-09 down ENSMUSG00000038145 mRNA Smrk 1.131226533 7.87E-12 1.93E-08 up ENSMUSG0000006755 mRNA Korc111 -1.25206046 9.43E-09 1.80E-05 down ENSMUSG00000045573 mRNA Vkorc111 -1.25206046 9.43E-09 1.80E-05 down ENSMUSG00000045573 mRNA Gm21953 4.894733705 1.36E-06 0.001646706 down ENSMUSG	11 5		J 1	8			8 1
ENSMUSG000003300mRNAHn12.816998186.35E-165.45E-12upENSMUSG000003181mRNASle3a21.403245831.44E-158.24E-12upENSMUSG000003244mRNANgm-3.032195407.0E-133.09E-04domENSMUSG000003245mRNAPedng42.444296311.31E-124.50E-09upENSMUSG000003310mRNA7.32440D04Rik2.641215913.16E-129.03E-09upENSMUSG000003451mRNAGm32142.672129765.69E-101.22E-06domENSMUSG000006755mRNAGm12057.723717532.09E-081.80E-05domENSMUSG000004575mRNAFalte1.488798701.15E-060.0164707domENSMUSG000004575mRNAGm12051.588198744.09E-060.0457924domENSMUSG000004575mRNAFras1.318186744.09E-060.0457924domENSMUSG000004575mRNAFras1.318186744.09E-060.0457924domENSMUSG000004526mRNAFras1.318186744.09E-060.0457924domENSMUSG00000539mRNAFras1.35816741.01E-050.00457924domENSMUSG000005450mRNAFras1.358712631.02E-050.00457121domENSMUSG000005450mRNAFras1.358712631.58E-050.01216126domENSMUSG000005451mRNAFras1.358174531.94E-050.2167648domENSMUS	id	type	name	log2FC(GD/GC)	pval	fdr	regulate
No.No.NameSiedaac1.4032458351.44E-16R.24E-12upENSMUSG0000032484MRNANgp3.032195497.20E-133.09E-90downENSMUSG0000010367mRNAPodga42.4442950011.31E-124.50E-00downENSMUSG0000003141mRNASnrk1.1312265337.87E-129.03E-00dpENSMUSG0000003145mRNASnrk1.1312265337.87E-121.22E-06downENSMUSG000006753mRNAGm32142.2672179765.69E-101.22E-06downENSMUSG000006753mRNAKorcl11-1.225006469.43E-001.80E-00downENSMUSG0000007553mRNAGm142057.7237175332.09E-080.0161470downENSMUSG0000007553mRNAGm219534.8947337051.3EE-000.0014702downENSMUSG0000007553mRNARNA1.319162424.09E-000.00457924downENSMUSG0000001544mRNARbp3-1.3141440524.27E-000.00457924downENSMUSG0000005459mRNAZf2604-1.5784639621.02E-050.0023512downENSMUSG0000005491mRNAZf260-1.48530431.5E-050.0126103dupENSMUSG000003519mRNAFane-1.41530431.5E-050.0126164downENSMUSG000000531mRNAFane-1.41530431.5E-050.0216734downENSMUSG000000533mRNAFane-1.4171088643.36E-050.2167646 </td <td>ENSMUSG0000054074</td> <td>mRNA</td> <td>Skida1</td> <td>-4.059131148</td> <td>4.22E-47</td> <td>7.25E-43</td> <td>down</td>	ENSMUSG0000054074	mRNA	Skida1	-4.059131148	4.22E-47	7.25E-43	down
ENSMUSG0000032484mRNAMgp-3.0321954917.20E-13.3.09E-09downENSMUSG0000013677mRNAPedhga4-2.4442965011.31E-12.4.50E-00upENSMUSG00000038145mRNA4732440D44Rik2.6412159143.16E-12.9.03E-00upENSMUSG0000013815mRNASmk1.1312265337.87E-12.1.93E-08upENSMUSG000006755mRNAGm3214.2.6721297665.69E-10.1.22E-06downENSMUSG000006755mRNAVorc111.1.225006946.9.43E-09.1.80E-05downENSMUSG0000006755mRNAPenk.1.4987987921.15E-06.0.01646706downENSMUSG0000007555mRNAGm21953.4.894733701.36E-06.0.0181382upENSMUSG0000007555mRNARhp3.1.5189167424.09E-06.0.04579247downENSMUSG0000001535mRNAThf.1.3193624238.39E-06.0.04579247downENSMUSG0000005459mRNAZfp20.1.518-163.0.0281512.0.00.0.01ENSMUSG0000005110mRNAKmp3.1.518-5126.0.01923551.0.00.0.01ENSMUSG0000005131mRNAPip126.1.31875126.1.5E-05.0.01216316.0.01ENSMUSG0000007534mRNAFport.1.5104532.44E-05.0.2167348.0.2167348.0.2167348ENSMUSG0000007534mRNAFport.1.17108864.3.6E-05.0.2167348.0.2167348.0.2167348.0.2167348<	ENSMUSG0000053004	mRNA	Hrh1	2.816998418	6.35E-16	5.45E-12	up
r. r. ENSMUSG00000103677 mRNA Pcdbga4 -2.444296501 1.31E-12 4.50E-09 qw ENSMUSG0000000031 lncRNA 4732440D04Rik 2.641215914 3.16E-12 9.03E-09 qw ENSMUSG000000038145 mRNA Smk 1.131226533 7.87E-12 1.93E-08 qw ENSMUSG0000006673 mRNA Gm39214 -2.672129766 5.69E-10 1.22E-06 down ENSMUSG0000006753 mRNA Gm14205 7.723717533 2.09E-08 3.59E-05 qw ENSMUSG00000045573 mRNA Gm14205 7.149879872 1.15E-06 0.00164706 down ENSMUSG00000045853 mRNA Gm21953 4.89473375 1.36E-06 0.00457927 down ENSMUSG00000045853 mRNA Rbp3 -1.48978622 4.09E-06 0.00457927 down ENSMUSG00000045829 mRNA Rbp3 -1.48918672 4.09E-06 0.00457927 down ENSMUSG0000005319 mRNA Chp260 -1.75846392 1.5E-05	ENSMUSG0000038178	mRNA	Slc43a2	1.403245835	1.44E-15	8.24E-12	up
ENSMUSG00000090031 IncRNA 4732440D04Rik 2.641215914 3.16E-12 9.03E-09 up ENSMUSG0000038145 mRNA Smk 1.131226533 7.87E-12 1.93E-08 up ENSMUSG00000109754 IncRNA Gm39214 2.672129766 5.69E-10 1.22E-06 down ENSMUSG0000066753 mRNA Kore111 -1.225006946 9.43E-09 1.80E-05 up ENSMUSG00000045573 mRNA Gm14205 7.723717533 2.09E-08 .001646706 down ENSMUSG00000045573 mRNA Gm21953 4.89473375 1.36E-06 0.00146702 down ENSMUSG00000027852 mRNA Kras -1.589186742 4.09E-06 0.004579247 down ENSMUSG00000041534 mRNA Rhp3 -1.34144052 4.27E-06 0.009235512 down ENSMUSG00000049249 mRNA Zfp260 -1.758463962 1.02E-05 0.00923512 down ENSMUSG00000053119 mRNA Pp1r261 1.48530434 1.79E-05 0.01268064 down <td>ENSMUSG0000032484</td> <td>mRNA</td> <td>Ngp</td> <td>-3.032195491</td> <td>7.20E-13</td> <td>3.09E-09</td> <td>down</td>	ENSMUSG0000032484	mRNA	Ngp	-3.032195491	7.20E-13	3.09E-09	down
ENSMUSG0000038145mRNASmk1.1312265337.87E-121.93E-08upENSMUSG00000109754lncRNAGm39214-2.6721297665.69E-101.22E-06downENSMUSG0000066755mRNAVkore111-1.2250069469.43E-091.80E-05downENSMUSG0000005750mRNAGm142057.7237175332.09E-083.59E-05downENSMUSG00000045753mRNAPenk-1.4987987921.15E-060.001646706downENSMUSG0000027855mRNAGm219534.8947337051.36E-060.001801382upENSMUSG0000027850mRNARbg3-1.3414440524.09E-060.004579247downENSMUSG0000004154mRNARbg3-1.3414440524.09E-060.004570247downENSMUSG0000004154mRNAKp260-1.7584639621.02E-050.00245512downENSMUSG00000049421mRNAChmp3-1.1643336281.5E-050.01271231upENSMUSG0000005319mRNAPp12641.485304341.79E-050.01268064downENSMUSG0000002771mRNAEp0-4.305005392.88E-050.02167348downENSMUSG0000004523mRNAScmat-1.171088643.36E-050.02167348downENSMUSG0000007534mRNAScmat-1.9790743.46E-050.02167348downENSMUSG0000004252mRNAScmat1.19790543.36E-050.02167348downENSMUSG0000004253mRNAScmat1.1979054 <td>ENSMUSG00000103677</td> <td>mRNA</td> <td>Pcdhga4</td> <td>-2.444296501</td> <td>1.31E-12</td> <td>4.50E-09</td> <td>down</td>	ENSMUSG00000103677	mRNA	Pcdhga4	-2.444296501	1.31E-12	4.50E-09	down
ENSMUSG0000109754IncRNAGm392142.6721297665.69E-101.22E-06downENSMUSG0000066755mRNAVkore1l1-1.2250069469.43E-091.80E-0500ENSMUSG0000005753mRNAGm142057.7237175332.09E-083.59E-06000ENSMUSG0000094557mRNAPenk-1.498798721.15E-060.00164702000ENSMUSG0000094565mRNAGm219534.8947337051.36E-060.00457924700ENSMUSG0000001534mRNAKbp3-1.341440524.27E-060.00457924700ENSMUSG00000041543mRNAKbp3-1.1643362428.39E-060.00847032700ENSMUSG0000005310mRNAChmp3-1.1643362431.5E-050.0098495700ENSMUSG0000005310mRNAKmaek1.3587512631.5E-050.00984957000ENSMUSG0000005310mRNAFpo1261.48530441.79E-050.012731230000ENSMUSG0000027711mRNAEpo4.305053992.88E-050.0216736400000ENSMUSG0000007533mRNAKram-1.110888643.36E-050.02167364000000000000000000000000000000000 <t< td=""><td>ENSMUSG0000090031</td><td>lncRNA</td><td>4732440D04Rik</td><td>2.641215914</td><td>3.16E-12</td><td>9.03E-09</td><td>up</td></t<>	ENSMUSG0000090031	lncRNA	4732440D04Rik	2.641215914	3.16E-12	9.03E-09	up
ENSMUSG000006753mRNAVkorc111-1.2250069469.43E-091.80E-09downENSMUSG000007530lnGRNAGm142057.7237175332.09E-083.59E-06001ENSMUSG000004553mRNAPenk-1.498798721.15E-060.001647040wENSMUSG000007650mRNAGm219534.8947337051.36E-060.0045792470wENSMUSG0000004153mRNANras-1.5891867424.09E-060.0045792470wENSMUSG0000004154mRNARbp3-1.3141440524.27E-060.008470320wENSMUSG0000004154mRNAZfp260-1.7584639621.02E-050.00924512dwnENSMUSG0000004121mRNAZfp260-1.7584639621.02E-050.00924512dwnENSMUSG0000035309mRNARansek1.3587512631.56E-050.01293512upENSMUSG0000035309mRNAPp17261.48530431.79E-050.02167304dwnENSMUSG000004523mRNASp11211.926173532.94E-050.02167304dwnENSMUSG000004523mRNASca321.197095443.36E-050.022167348dwnENSMUSG000004524mRNASca131.197095443.36E-050.02167364upENSMUSG000004525mRNASca131.197095443.36E-050.02167348upENSMUSG000003879mRNASca121.485104125.47E-050.0312668upENSMUSG000003879mRNASca121.485104125.47E-050	ENSMUSG0000038145	mRNA	Snrk	1.131226533	7.87E-12	1.93E-08	up
ENSMUSG0000087563IncRNGml42057.723717532.09E-083.59E-08upENSMUSG0000045573mRNAPenk-1.498798721.15E-080.00164706downENSMUSG0000026863mRNAGm219534.894733701.36E-080.00187102downENSMUSG0000027852mRNANras-1.5891867424.09E-080.004579247downENSMUSG0000005853mRNARbp3-1.34144054.27E-080.004579247downENSMUSG0000005854mRNATh2.1393624238.39E-080.00847032downENSMUSG000005910mRNAZfp260-1.758463961.0E-050.00923512downENSMUSG000005311mRNAChmp3-1.164336281.5E-050.01273123downENSMUSG000005329mRNAPp12631.485304341.79E-050.013058752upENSMUSG000005329mRNAFor-1.16133532.94E-050.02167348downENSMUSG000005329mRNARom-1.171088643.36E-050.02167348downENSMUSG000004523mRNAScab21.1970543.46E-050.02167348downENSMUSG000004524mRNAScab21.19705443.46E-050.02167348quENSMUSG000004525mRNAScab21.19705443.46E-050.02167348quENSMUSG000004526mRNAScab21.185104125.47E-050.0312668quENSMUSG000004526mRNAScab21.19705443.46E-050.02167348 <td>ENSMUSG00000109754</td> <td>lncRNA</td> <td>Gm39214</td> <td>-2.672129766</td> <td>5.69E-10</td> <td>1.22E-06</td> <td>down</td>	ENSMUSG00000109754	lncRNA	Gm39214	-2.672129766	5.69E-10	1.22E-06	down
A C C C NSMUSG000004557nRNAPenk-1.498798791.15E-100.00164700downENSMUSG000002469mRNAGm219534.8947337051.36E-000.00180132upENSMUSG0000027852mRNANras-1.5891867424.09E-000.004579247downENSMUSG0000004153mRNARbp3-1.341440524.27E-000.004579247downENSMUSG0000005829mRNATh2.1393624238.39E-000.008470327upENSMUSG000005410mRNAZfp260-1.7584639621.02E-050.009235512downENSMUSG000005310mRNAChmp3-1.1643336281.5E-050.012731231upENSMUSG000003582mRNAPp1261.485304341.79E-050.01398752upENSMUSG000004523mRNAEpo-4.305005392.88E-050.02167348downENSMUSG000004523mRNAScan21.19705443.36E-050.02167348upENSMUSG000004524mRNAScan31.19790543.440E-050.02167348upENSMUSG000004525mRNAScan21.485104125.4TE-050.0313268upENSMUSG000003797mRNAScan21.485104125.4TE-050.0313268upENSMUSG000003797mRNAScan21.485104125.4TE-050.0313268upENSMUSG000003797mRNAScan21.485104125.4TE-050.0313268upENSMUSG000003797mRNAScan21.485104125.4TE-05	ENSMUSG0000066735	mRNA	Vkorc111	-1.225006946	9.43E-09	1.80E-05	down
ENSMUSG000009469mRNAGm219534.894733701.36E-060.001801382upENSMUSG000002782mRNANras-1.5891867424.09E-060.004579247downENSMUSG0000004153mRNARbp3-1.341444024.27E-060.004579247downENSMUSG00000049420mRNATrh2.1393624238.39E-060.00923512downENSMUSG00000049421mRNAZfp260-1.7584639621.02E-050.00923512downENSMUSG0000039309mRNAChmp3-1.164333621.5E-050.012731231upENSMUSG0000039309mRNAPp17261.48530431.79E-050.01208064downENSMUSG000002711mRNAEpo-4.3050053992.88E-050.021068064downENSMUSG0000075334mRNARama-1.1710888643.66E-050.021073143downENSMUSG0000075334mRNAScab1.19705443.66E-050.02107348dpENSMUSG000004252mRNAScab1.19705443.66E-050.02107348dpENSMUSG000004252mRNAScab1.19705443.66E-050.02107348dpENSMUSG0000037374mRNAScab1.19705443.66E-050.02107348dpENSMUSG000003539mRNAScab1.19705443.66E-050.02107348dpENSMUSG000003539mRNAScab1.19705443.66E-050.02107434dpENSMUSG000003539mRNAScab1.19705443.66E-050.0313268<	ENSMUSG0000087563	lncRNA	Gm14205	7.723717533	2.09E-08	3.59E-05	up
Instruction Instruction <thinstruction< th=""> <thinstruction< th=""></thinstruction<></thinstruction<>	ENSMUSG0000045573	mRNA	Penk	-1.498798792	1.15E-06	0.001646706	down
ENSMUSG0000041154mRNARbp3-1.341444024.2TE-060.004579247downENSMUSG000005540mRNATh2.139362428.39E-060.00847032upENSMUSG000005411mRNAZfp260-1.7584639621.02E-050.009235512downENSMUSG0000053109mRNAChmp3-1.1643336281.56E-050.01273121upENSMUSG0000035829mRNAPp1r261.485304341.79E-050.013958752upENSMUSG0000029711mRNAEpo-4.3050053992.88E-050.02166804downENSMUSG0000045235mRNAA73035117Rik-1.926173532.94E-050.02167348downENSMUSG0000045236mRNARpm-1.171088843.36E-050.022167348upENSMUSG0000045235mRNASca321.19790543.46E-050.02167348upENSMUSG000004253mRNAScan21.485104125.47E-050.0313268upENSMUSG000004534mRNAScan21.485104125.47E-050.0313268upENSMUSG000004253mRNAGma21.45114125.47E-050.0313268upENSMUSG000004534mRNAScan21.485104125.47E-050.0313268upENSMUSG000004545mRNAGma21.45114125.47E-050.0313268upENSMUSG000004545mRNAGma21.45114125.47E-050.0313268upENSMUSG000004545mRNAGma21.551161515.83E-050.03220674up<	ENSMUSG0000094695	mRNA	Gm21953	4.894733705	1.36E-06	0.001801382	up
ENSMUSG0000005892mRNATrh2.1393624238.39E-060.008470327upENSMUSG0000049421mRNAZfp260-1.7584639621.02E-050.00923512downENSMUSG0000053119mRNAChmp3-1.1643336281.15E-050.00984957downENSMUSG0000035829mRNARnasek1.3587512631.56E-050.012731231upENSMUSG0000035829mRNAPp1r261.485304341.79E-050.012068064downENSMUSG0000045238incRNAEpo-4.305005992.88E-050.021068064downENSMUSG0000075334incRNAA730035117Rik-1.926173532.94E-050.022167348downENSMUSG0000042528incRNAScn3b-1.1710888643.36E-050.022167348downENSMUSG0000042524mRNAScn3b1.197905443.36E-050.022167348upENSMUSG0000045254mRNAScn3b1.197905443.36E-050.021068064upENSMUSG0000042524mRNAScn3b1.197905443.36E-050.022167348upENSMUSG0000045254mRNAScan21.485104125.47E-050.03132668upENSMUSG0000014674incRNAScan21.485104125.47E-050.03229673up	ENSMUSG0000027852	mRNA	Nras	-1.589186742	4.09E-06	0.004579247	down
ENSMUSG0000049421 mRNA Zfp260 -1.758463962 1.02E-05 0.00923512 down ENSMUSG0000053119 mRNA Chmp3 -1.164333628 1.15E-05 0.00984957 down ENSMUSG0000035319 mRNA Rnasek 1.358751263 1.56E-05 0.012731231 up ENSMUSG0000035829 mRNA Ppp1r26 1.48530434 1.79E-05 0.013958752 up ENSMUSG0000029711 mRNA Epo -4.305005399 2.88E-05 0.021068064 down ENSMUSG00000045238 IncRNA A730035117Rik -1.926173533 2.94E-05 0.021068064 down ENSMUSG00000075334 mRNA Scn3b -1.171088864 3.36E-05 0.022167348 down ENSMUSG00000042523 mRNA Scn3b 1.19790544 3.36E-05 0.027001684 up ENSMUSG00000038797 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG0000014674 incRNA Gm42756 1.531618517 5.83E-05 0.032296743 u	ENSMUSG00000041534	mRNA	Rbp3	-1.341444052	4.27E-06	0.004579247	down
ENSMUSG0000053119mRNAChmp3-1.1643336281.15E-050.00984957downENSMUSG0000039399mRNARnasek1.3587512631.56E-050.012731231upENSMUSG0000035829mRNAPpp1r261.485304341.79E-050.013958752upENSMUSG0000029711mRNAEpo-4.3050053992.88E-050.021068064downENSMUSG0000045238incRNAA730035117Rik-1.926173532.94E-050.021068064downENSMUSG0000075334mRNARprm-1.1710888643.36E-050.022167348downENSMUSG0000042523mRNAScn3b1.197905443.36E-050.022167348upENSMUSG0000038797mRNAZscan21.4851041215.47E-050.03132668upENSMUSG000014644incRNAGm427561.5316185175.83E-050.032296743up	ENSMUSG0000005892	mRNA	Trh	2.139362423	8.39E-06	0.008470327	up
ENSMUSG0000093989mRNARnasek1.3587512631.56E-050.012731231upENSMUSG0000035829mRNAPpp1r261.485304341.79E-050.013958752upENSMUSG0000029711mRNAEpo-4.3050053992.88E-050.021068064downENSMUSG0000045238lncRNAA730035117Rik-1.9261735332.94E-050.021068064downENSMUSG0000075334mRNARprm-1.1710888643.36E-050.022167348downENSMUSG0000042523mRNAScn3b1.197905443.36E-050.022167348upENSMUSG0000042523mRNAScna21.4851041215.47E-050.03132668upENSMUSG0000014674IncRNAGm427561.5316185175.83E-050.032296743up	ENSMUSG00000049421	mRNA	Zfp260	-1.758463962	1.02E-05	0.009235512	down
ENSMUSG0000035829 mRNA Ppp1r26 1.48530434 1.79E-05 0.013958752 up ENSMUSG0000029711 mRNA Epo -4.305005399 2.88E-05 0.021068064 down ENSMUSG0000045238 lncRNA A730035117Rik -1.926173533 2.94E-05 0.021068064 down ENSMUSG0000075334 mRNA Rprm -1.17108864 3.36E-05 0.022167348 down ENSMUSG0000042523 mRNA Scn3b 1.19790544 3.36E-05 0.022167348 up ENSMUSG0000042523 mRNA Dnal1 1.9593073 4.40E-05 0.02106804 up ENSMUSG0000014674 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG0000014674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG00000053119	mRNA	Chmp3	-1.164333628	1.15E-05	0.00984957	down
ENSMUSG0000029711 mRNA Epo -4.305005399 2.88E-05 0.021068064 down ENSMUSG0000045238 lncRNA A730035117Rik -1.926173533 2.94E-05 0.021068064 down ENSMUSG0000075334 mRNA Rprm -1.171088864 3.36E-05 0.022167348 down ENSMUSG0000049281 mRNA Scn3b 1.19790544 3.36E-05 0.022167348 up ENSMUSG0000042523 mRNA Dnal1 1.9593073 4.40E-05 0.027001684 up ENSMUSG0000014674 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG00000093989	mRNA	Rnasek	1.358751263	1.56E-05	0.012731231	up
ENSMUSG0000045238 lncRNA A730035117Rik -1.926173533 2.94E-05 0.021068064 down ENSMUSG0000075334 mRNA Rprm -1.171088864 3.36E-05 0.022167348 down ENSMUSG0000049281 mRNA Scn3b 1.19790544 3.36E-05 0.022167348 up ENSMUSG0000042523 mRNA Dnal1 1.9593073 4.40E-05 0.02106806 up ENSMUSG0000014674 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG0000035829	mRNA	Ppp1r26	1.48530434	1.79E-05	0.013958752	up
ENSMUSG0000075334mRNARprm-1.1710888643.36E-050.022167348downENSMUSG0000049281mRNAScn3b1.197905443.36E-050.022167348upENSMUSG0000042523mRNADnal11.95930734.40E-050.027001684upENSMUSG0000038797mRNAZscan21.4851041215.47E-050.03132668upENSMUSG0000104674IncRNAGm427561.5316185175.83E-050.032296743up	ENSMUSG0000029711	mRNA	Еро	-4.305005399	2.88E-05	0.021068064	down
ENSMUSG0000049281 mRNA Scn3b 1.19790544 3.36E-05 0.022167348 up ENSMUSG0000042523 mRNA Dnal1 1.9593073 4.40E-05 0.027001684 up ENSMUSG00000038797 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG0000045238	lncRNA	A730035I17Rik	-1.926173533	2.94E-05	0.021068064	down
ENSMUSG00000042523 mRNA Dnal1 1.9593073 4.40E-05 0.027001684 up ENSMUSG00000038797 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG00000075334	mRNA	Rprm	-1.171088864	3.36E-05	0.022167348	down
ENSMUSG00000038797 mRNA Zscan2 1.485104121 5.47E-05 0.03132668 up ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG00000049281	mRNA	Scn3b	1.19790544	3.36E-05	0.022167348	up
ENSMUSG00000104674 lncRNA Gm42756 1.531618517 5.83E-05 0.032296743 up	ENSMUSG0000042523	mRNA	Dnall	1.9593073	4.40E-05	0.027001684	up
	ENSMUSG0000038797	mRNA	Zscan2	1.485104121	5.47E-05	0.03132668	up
ENSMUSG00000001119 mRNA Col6a1 -1.139747859 7.57E-05 0.038251241 down	ENSMUSG00000104674	lncRNA	Gm42756	1.531618517	5.83E-05	0.032296743	up
	ENSMUSG0000001119	mRNA	Col6a1	-1.139747859	7.57E-05	0.038251241	down

Supplementary Table. Differentially expressed genes between control and PPD group	ups
---	-----

Supplementary Table. Differentially expressed genes between control and PPD groups

To avoid false positive errors, multiple test correction method was used to correct the significant

p-value obtained from the original hypothesis test, and finally false discovery rate (FDR) was used as

key index for screening differentially expressed genes. FDR<0.05